Home / Clinical Decision Support & Reference / INIFY Prostate

INIFY Prostate

by ContextVision · Based in Sweden → — AI-based decision support for accurate prostate cancer diagnosis.

Oncology Pathology Urology

Website

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Overview

INIFY Prostate, developed by ContextVision and now part of Inify Laboratories, is an AI-based, CE-marked decision support tool designed for digital pathology. It is primarily intended for pathologists and uropathologists in care settings that utilize digital pathology workflows for prostate cancer diagnostics.

What it does: INIFY Prostate identifies and outlines suspicious cancer areas in digitized prostate needle biopsy slides stained with H&E. The initial version focuses on identifying cancerous tissues, with future iterations planned to suggest Gleason classifications.
How it fits a clinical workflow: The tool integrates into a digital pathology workflow, aiming to streamline the diagnostic process. It can help prioritize pathologists’ worklists by automatically separating slides containing cancer from those that do not, potentially presenting cases with more significant cancer first. This can contribute to more efficient analysis and reporting.
Notable capabilities: INIFY Prostate utilizes a patented annotation method called MasterAnnotation in its algorithm training, which contributes to its pixel-level focus in outlining suspicious areas. Clinical evaluations have indicated high sensitivity and specificity in identifying cancer, even in small foci. The tool is designed to work consistently across images from different pathology labs and scanners. Inify Laboratories emphasizes a specialized workflow dedicated to prostate biopsies, aiming for consistent quality and easily interpretable visual reports for urologists.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

AI-based decision support
Accurate outlining of suspicious prostate cancer areas
Pixel-level focus through MasterAnnotationu2122
High sensitivity (100% for small cancer foci, 99.3-99.8% for larger areas)
High specificity (96-98%)
Works equally well across different pathology labs and scanners
Supports pathologists in daily clinical work
Improves diagnostic confidence
Worst-case-first reviewing process for workflow management
Potential for Gleason grading suggestions (future version)

Use Cases

Identifying and outlining suspicious prostate cancer areas in digitized prostate biopsy slides
Supporting pathologists in their daily clinical work to increase diagnostic accuracy
Improving concordance between pathologists
Prioritizing patient cases with higher levels of cancer for diagnosis
Reducing inter- and intra-variability in prostate cancer diagnosis
Automating image analysis for efficiency and precision

What Physicians Need to Know

Evidence Base (literature scope)

INIFY Prostate is an AI-based, CE-marked decision support tool that identifies and outlines suspicious cancer areas in digitized prostate needle biopsy slides. [2, 4, 5] It utilizes a patented annotation method called MasterAnnotationu2122 for training its algorithms. [1, 3, 9] The tool is supported by peer-reviewed papers, including an evaluation of its diagnostic accuracy independent of preanalytical factors. [4, 7]

Clinical Validation Studies

Clinical evaluations have shown INIFY Prostate to accurately outline suspicious prostate cancer. [1] A US clinical evaluation, presented at the Pathology Visions Congress in 2021, involved two independent pathologists reviewing predictions on prostate biopsy slides from 30 patients across two medical centers and three different scanners. [1] This study demonstrated 100% sensitivity for images with small cancer foci (u22641 mm) and 99.3u201399.8% sensitivity for larger cancer areas, with a high specificity of 96u201398%. [1, 7] The study concluded that INIFY Prostate performs consistently across different pathology labs and scanners. [1, 7] The Pan-European multicenter clinical study 'FirstPath' also evaluated INIFY Prostate's performance in routine clinical practice across four sites, reviewing over 300 biopsy images from 48 patients. [3] This study reported a high sensitivity of 98% and specificity of 96% for correct cancer diagnosis, demonstrating robustness across sites, tissue preparation, scanning, and pathologists. [3] Another clinical evaluation studied the tool's ability to improve accuracy, concordance, and diagnostic confidence among pathologists. [5]

Alert Fatigue Management

INIFY Prostate aims to reduce pathologist workload and anxiety by reliably finding even the smallest cancer foci. [1, 5, 6] It presents cases with the most suspicious areas first, with an automatic calculation of the suspicious cancer area percentage in each slide, which can help streamline the review process. [3, 9]

Differential Diagnosis Support

The tool's primary function is to identify and outline areas suspicious for carcinoma in digitized prostate needle biopsy slides, aiding in prostate cancer detection and segmentation. [4, 5] It also supports Gleason grading. [4, 6, 9]

Clinical Workflow Integration

INIFY Prostate is designed for seamless integration into fully digitalized pathology workflows. [2, 5, 8] It pre-predicts and makes all slides examination-ready when a case is opened, and can present pathologists' worklists in a 'worst-first' order. [3, 9] The system is built to support efficient and standardized processes, aiming to save time for pathologists and ensure objective, consistent, and accurate evaluation of biopsies. [6, 8, 14]

Decision Audit Trail

While not explicitly detailed for INIFY Prostate, the importance of audit trails in electronic medical records for accountability and tracking changes is recognized in the healthcare industry. [23] Inify Laboratories emphasizes smooth, traceable logistics and process management systems that enable traceability in every step, from sample transport to final diagnosis. [11, 14]

Physician Tip

INIFY Prostate is an AI-powered tool designed to enhance the accuracy and efficiency of prostate cancer diagnosis from digitized biopsy slides. Pathologists should leverage its high sensitivity and specificity for identifying suspicious cancer areas, especially small foci, to increase diagnostic confidence and reduce the anxiety associated with missing important findings. The 'worst-first' presentation of cases and slides can help prioritize workload. The tool's robustness across different lab preparations and scanners suggests reliable performance in varied clinical settings. It is important to remember that this tool is a decision support system and the final diagnosis is always performed by a pathologist. [1, 3, 5, 6, 9, 14]

INIFY Prostate is an AI-based, CE-marked decision support tool that seamlessly integrates with hospital LIS systems and is designed for fully digitalized pathology workflows. [2, 8] It processes whole slide images (H&E stained) and is deployed as an external service. [4] The system is scalable for handling large volumes of patient samples and can be replicated in new locations. [14] Inify Laboratories also offers integrated services spanning from early sample handling to final diagnosis, optimizing quality and response times through a fully digital, standardized, and AI-assisted workflow. [14]

At a glance

Deployment External Service

Visit site

Details

Category	Clinical Decision Support & Reference, Oncology AI, Pathology AI
Pricing	Unknown — unknown
Deployment	External service
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	Unknown AI-estimated While INIFY Prostate is CE-marked for clinical use in the European Union, there is no information available to confirm FDA clearance for INIFY Prostate in the United States. Another AI-based software, Paige Prostate, received the first FDA authorization for AI in pathology for prostate cancer detection in 2021.
Integrations
EHR	Not specified
Specialties	Oncology, Pathology, Urology

What the Web Says

INIFY Prostate is an AI-based, CE-marked software designed to assist pathologists in detecting and outlining suspicious areas for carcinoma in digitized prostate needle biopsy slides. Clinical evaluations have shown it to be highly accurate and robust across different labs, tissue preparations, and scanners, with high sensitivity and specificity in identifying cancer. The software aims to improve diagnostic accuracy, consistency, and speed in prostate cancer diagnosis, potentially reducing pathologist workload and improving patient care.

Overall: Positive

Strengths

High sensitivity (99.3-100%) in identifying cancer, even small foci (<=1mm).
High specificity (95.5-98.5%) in correctly identifying benign tissue.
Robust performance across different pathology labs, tissue preparations, and scanners.
Improves diagnostic confidence and consistency among pathologists.
Intuitive, fast, and user-friendly viewer.
Speeds up the diagnostic process, with potential for quicker patient results.

Limitations

Validation summary not yet fully populated in some registries.
Some instances of false positives, though typically minute.
Specific details on integration and deployment are not widely available in public reviews.

Based on reviews from: ContextVision (Press Releases), PubMed, Oxford Calling, Health AI Register, ResearchGate, Inify Laboratories, OncologyAI Registry, Urology Partners

Last updated: 2026-08-08

Ratings & Reviews

Rate INIFY Prostate

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for INIFY Prostate.

Loading videos...

View all on YouTube

Frequently Asked Questions

How does INIFY Prostate integrate into existing clinical workflows for prostate cancer diagnosis?

INIFY Prostate is an AI-based, CE-marked decision support tool designed to seamlessly integrate into a fully digitalized pathology workflow. It identifies and outlines suspicious cancer areas in digitized prostate biopsy samples, aiming to support pathologists in their daily clinical work and improve diagnostic confidence.

What is the evidence for INIFY Prostate's diagnostic accuracy and reliability?

Clinical evaluations have shown high accuracy for INIFY Prostate. In one study, it achieved 100% sensitivity for small cancer foci (u22641 mm) and 99.3-99.8% sensitivity for larger cancer areas, with a high specificity of 96-98%. The tool has also demonstrated robustness across different labs, tissue preparations, scanners, and pathologists.

Are there any known limitations or challenges associated with using INIFY Prostate?

While INIFY Prostate has shown strong performance, one study noted a limitation in that both participating laboratories were academic centers, suggesting a need for additional studies to assess performance in community hospitals and reference laboratories. The effectiveness of AI tools can also be influenced by variations in image quality, though INIFY Prostate aims to minimize these through standardized processes.

What are the alternatives to INIFY Prostate for prostate cancer diagnosis and clinical decision support?

Alternatives to AI-powered decision support tools like INIFY Prostate include other AI solutions for prostate pathology such as Aira Matrix, ArteraAI, Deep Bio, Ibex Medical Analytics, and Mindpeak. For initial prostate cancer screening and risk assessment, alternatives to biopsy include enzyme tests (like PSA), watchful waiting, MRI scans, digital rectal exams (DRE), transrectal ultrasounds (TRUS), and urine tests (e.g., PCA3, MiPS).

What is the pricing model for INIFY Prostate, and how does it compare to other diagnostic methods?

The provided information does not specify the pricing model for INIFY Prostate. However, the company emphasizes that powerful decision support tools like INIFY Prostate have the potential to save valuable time for pathologists and ensure a more objective, consistent, and accurate evaluation of biopsies, which can indirectly impact costs by improving efficiency.